Introduction

If you are the parent of a child whose head or hands appear different, you may notice challenges with breathing, hearing, or vision. Pfeiffer syndrome is a genetic disorder that changes the shape of the head and face. It is caused by early fusion of some skull bones and can lead to differences in the hands and feet. For parents of children with Pfeiffer syndrome, it can be challenging to perform daily routines. Many parents seek answers to understand why their child is affected and what treatment options are available.   

Pfeiffer syndrome

Pfeiffer syndrome is a rare genetic condition that affects approximately 1 in 100,000 people. In the skull, this early bone formation causes craniosynostosis, which means that certain bones fuse too soon. In limbs, normal growth of fingers and toes is disrupted, and often there is partial webbing between fingers and toes. Other traits include hearing and vision problems, hydrocephalus (an abnormal buildup of cerebrospinal fluid within the brain), and developmental delays. Breathing difficulties can also occur due to an underdeveloped midface, and in rare cases, the windpipe may also be affected.¹

Pfeiffer syndrome is caused by mutations in genes responsible for growth and development; hence, genetics plays a central role in understanding the condition. This article explores recent advances in genetic research and potential therapies for Pfeiffer syndrome.

Genetic basis of pfeiffer syndrome

Role of FGFR1 and FGFR2 gene mutations

Pfeiffer syndrome results from a ‘gain-of-function mutation’ in the FGFR1 or FGFR2 (Fibroblast Growth Factor Receptor) genes, increasing fibroblast growth factor receptor protein activity. This heightened, prolonged signalling leads to early bone cell maturation, as these receptors regulate cell growth, division, and development. A single altered gene copy usually causes the disorder. Mutations in either FGFR1 or FGFR2 can lead to the standard form of Pfeiffer syndrome, while severe forms are mainly due to FGFR2 mutations.¹

Variability of symptoms depending on mutation type

The mutated FGFR gene, the location of the mutation, and the degree of receptor alteration all affect symptom severity. FGFR2 mutations typically result in more severe forms.

Based on how severe the traits are, three subtypes of Pfeiffer syndrome are recognised. The following descriptions outline the typical features of each type.

• Type 1: The classic, mildest form is characterised by skull changes, broad thumbs and toes, normal intelligence, and generally good outcomes
• Type 2: More severe, with extreme skull changes, cloverleaf skull, prominent eyes, stiff or fused elbows, developmental delays, and severe neurological and vision problems
• Type 3: Similar to type 2 but lacks a cloverleaf skull, making diagnosis more difficult

Types 2 and 3 are usually sporadic, not inherited, and carry higher risks of early death from severe brain and breathing complications. Some overlap exists between all three Pfeiffer syndrome types.¹

Diagnosing Pfeiffer syndrome is challenging because its symptoms resemble other craniosynostosis conditions. Many, such as Apert, Crouzon, and Muenke syndromes, involve changes in the same genes, leading to overlapping symptoms. For example, Crouzon syndrome is similar to Pfeiffer but does not affect the hands and feet, while broad toes may also appear in Jackson-Weiss syndrome. This overlap makes genetic testing crucial for accurate diagnosis and treatment.¹

Recent advances in genetic research

Traditional diagnostic approaches

Most cases of Pfeiffer syndrome are diagnosed after birth. Doctors carefully look at a baby’s appearance and check for unusual skull or limb shapes during a physical examination. Imaging tests, such as CT scans (Computed Tomography Scans) or MRIs (Magnetic Resonance Imaging), are often used to assess how the bones have formed and whether any are fused too early.

​Sometimes, doctors may suspect Pfeiffer syndrome even before birth using a prenatal ultrasound or fetal MRI. These tests can show early signs that a baby’s skull or facial bones are developing differently. To confirm the diagnosis, genetic testing can be done to check for changes in the FGFR1 or FGFR2 genes, which are known to cause Pfeiffer syndrome. Genetic testing can give a clear answer and can also help families understand the risk of the condition in future pregnancies.²

Early diagnosis through prenatal and postnatal genetic screening

Recent advances have enabled the diagnosis of Pfeiffer syndrome with greater precision before the child is born. Recent advancements include the use of high-resolution prenatal ultrasound to detect hallmark signs, such as a “cloverleaf” skull shape and underdeveloped midface structures, at approximately 29 weeks of gestation. Further confirmation of the diagnosis is done using Next-generation Sequencing, which identified a damaging change in the FGFR2 gene. This combined imaging-and-genetics approach allows for earlier recognition, more accurate counselling for parents, and better preparation for specialist care after birth.³

Genetic testing has advanced significantly, providing doctors with new tools to understand and diagnose health conditions associated with our DNA. Tools like chromosomal microarray analysis (CMA) help doctors see details that older tests might miss. CMA can detect subtle changes in chromosomes, such as small deletions or duplications, which can explain developmental issues or birth-related conditions. NGS goes even further, looking across the entire genome to uncover subtle differences, especially when other tests don’t give clear answers.⁴

By contrast, traditional diagnosis usually happens after birth, when a baby’s physical features are apparent. This can delay recognition of severe cases, reduce time for prenatal counselling, and make planning care more difficult for families. Newer prenatal methods, including imaging and genetic testing, can sometimes detect Pfeiffer syndrome before birth. These tests provide doctors with a clearer picture of a child’s genetic makeup, help guide care planning, and enable families to prepare for the support their child may need. It is also essential to explain results carefully and provide emotional support, especially if unexpected findings arise.

Better understanding of gene–trait correlations

Doctors are learning more about how specific gene changes influence the appearance of Pfeiffer syndrome in each individual. Mutations in the FGFR2 gene cause most cases, and less often in FGFR1. These mutations don’t all act the same; some are linked with very severe forms, such as type II, where babies may develop a cloverleaf-shaped skull and have serious health problems. Others lead to milder forms, affecting mainly the shape of the skull, hands, or feet. For example, a recent report described a new FGFR2 mutation (not previously reported) that caused Pfeiffer type II. The individual exhibited classic Type II features, including cloverleaf skull deformity, midfacial hypoplasia, and ocular proptosis. Despite being initially classified as nonpathogenic, the mutation was later reclassified as pathogenic, underscoring the evolving nature of genetic interpretation.⁵ 

At the same time, the picture is not always simple. Even when two people have the same mutation, the severity of their features can differ. Some FGFR2 mutations can even resemble other syndromes, which makes diagnosis more challenging. Careful clinical evaluation, combined with genetic testing, is the best way to resolve these overlaps and provide families with clear answers. This growing knowledge enables doctors to provide more accurate diagnoses and guidance, and in some cases, it can even inform treatment decisions.⁶

Use of animal models and cellular studies

Recent research using animals and lab-grown cells has helped scientists gain a deeper understanding of how Pfeiffer syndrome develops. In mice with FGFR2 mutations, abnormal activity of this gene during early growth disrupts the formation of bone and cartilage in the skull and jaw. These early changes help explain the unusual head and facial shapes seen in babies with the condition, such as prematurely fused skull bones and altered facial structure. These studies demonstrate the importance of regular FGFR2 activity in the proper development of the skull and bones.^7,8 

Researchers can also study Pfeiffer syndrome using induced pluripotent stem cells (iPSCs), which are made from patients’ cells and offer a human model. These cells exhibit the same abnormal FGFR2 activity observed in individuals with the syndrome. Scientists can use them to explore precisely how the mutation affects development and to test potential treatments, such as ways to reduce the overactive gene.⁹

Together, these animal and cellular studies help researchers connect the genetic changes to the physical features of Pfeiffer syndrome, opening new paths toward possible future therapies.

Current treatment approaches

Treatment for Pfeiffer syndrome aims to help with the differences in the skull, face, and limbs that the condition causes. Many children require surgery early on to correct skull shape, relieve pressure on the brain, and enhance the appearance and function of their face. These surgeries can involve reshaping the skull, moving the middle part of the face forward to improve breathing and appearance, and correcting issues with the jaw or limbs.

​In addition to surgery, a team of specialists provides comprehensive supportive care, including services from speech, physical, and occupational therapists, as well as specialists in eye and ear care. Each treatment plan is tailored to the child’s specific needs to ensure the best outcomes.¹⁰

Potential future therapies

Several alternative therapies are being tested, which have the potential to complement or even replace traditional therapies.

siRNA therapy

Existing therapies are evolving to target the genetic cause of Pfeiffer syndrome. Small interfering RNA (siRNA) can “turn off” the faulty FGFR2 gene while leaving the normal copy intact, thereby reducing the overactive signals that drive abnormal skull development. As this strategy has been used in Crouzon syndrome, the similar FGFR2 mutations in Pfeiffer syndrome suggest siRNA could offer a non-invasive therapy that addresses the underlying problem rather than just managing symptoms.¹¹

Hormone therapy

Following genetic-based strategies, hormonal approaches also represent promising avenues for future care. Some individuals with FGFR2 (fibroblast growth factor receptor 2) mutations may exhibit delayed growth, although short stature is not a typical feature of this condition. Treating patients with Pfeiffer syndrome using recombinant growth hormone, a laboratory-produced form of the hormone that stimulates growth, may be beneficial. Growth hormone therapy can help improve height even when the bone age is more advanced than expected. This therapy can complement surgical and supportive care.¹²

Stem cell therapy

Building on these developments, researchers are also exploring cellular approaches. Stem cell therapy could help treat Pfeiffer syndrome in the future. These cells can become bone or cartilage and may help rebuild parts of the skull and face. Guiding cells to prevent early fusion could provide a novel approach in conjunction with traditional surgery. ¹³

Ethical and practical considerations

Genetic therapies for rare conditions like Pfeiffer syndrome bring hope, but they also come with challenges. Because we do not yet know all the long-term effects, patients will need regular check-ups for years to watch for any late complications. 

Families should receive clear information about what is known and what is still uncertain, so they can make informed decisions about the risks and benefits. It is essential to balance trying new treatments with caution, always keeping the child's privacy and well-being in mind.¹⁴

Access and cost are significant concerns. Gene therapy or complex surgeries are often expensive and usually only available at specialised centres. This can make it difficult for some families to get the care they need, raising questions about equity. 

Patient registries and collaboration worldwide are crucial for advancing rare disease research. Registries help track disease progression, collect long-term data, and support research. By sharing data between countries and institutions, these systems enhance safety, facilitate the design of better studies, and ensure that new advances reach a broader patient population.¹⁵

Summary

• Pfeiffer syndrome is a rare genetic condition resulting from mutations in the FGFR1 or FGFR2 genes. It leads to early fusion of skull bones and differences in the hands and feet, and may cause breathing, vision, and hearing problems
• Traditional treatment focuses on surgery and supportive therapies to correct skull shape, improve function, and support development
• Recent progress in genetic research has made it easier to diagnose Pfeiffer syndrome early, thanks to advancements in prenatal imaging and genetic testing. This helps families get ready sooner
• Researchers are also learning how specific gene changes affect the severity of the condition by studying both animal models and stem cells from patients. These discoveries could lead to new treatments, including gene-targeted therapies, hormone treatments, and stem cell approaches
• While these future therapies hold promise, they also raise important ethical and practical considerations, including long-term safety, accessibility, cost, and the need for international collaboration through patient registries